Review
doi: 10.1016/j.ccr.2009.12.033.
HELP for AML: methylation profiling opens new avenues
Affiliations
- PMID: 20129241
- DOI: 10.1016/j.ccr.2009.12.033
Item in Clipboard
Review
HELP for AML: methylation profiling opens new avenues
Cancer Cell.
.
Free article
Abstract
There is growing evidence that aberrant gene expression in cancer is linked to epigenetic deregulation like promoter cytosine methylation in CpG-islands. In this issue of Cancer Cell, Figueroa et al. show that genome-wide promoter DNA methylation profiling reveals unique AML subgroups and methylation patterns that are associated with clinical outcome.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Comment on
-
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.Cancer Cell. 2010 Jan 19;17(1):13-27. doi: 10.1016/j.ccr.2009.11.020. Epub 2010 Jan 7. Cancer Cell. 2010. PMID: 20060365 Free PMC article.
Similar articles
-
Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.Ann Hematol. 2005 Dec;84 Suppl 1:39-46. doi: 10.1007/s00277-005-0005-0. Ann Hematol. 2005. PMID: 16231140
-
DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights.Future Oncol. 2010 Sep;6(9):1415-31. doi: 10.2217/fon.10.110. Future Oncol. 2010. PMID: 20919827 Review.
-
Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.Cancer Res. 2006 Jun 15;66(12):6118-28. doi: 10.1158/0008-5472.CAN-06-0376. Cancer Res. 2006. PMID: 16778185
-
Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.Ann Hematol. 2008 Oct;87(10):809-18. doi: 10.1007/s00277-008-0514-8. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587578
-
DNA methylation as a pathogenic event and as a therapeutic target in AML.Cancer Treat Rev. 2011;37 Suppl 1:S13-8. doi: 10.1016/j.ctrv.2011.04.013. Epub 2011 May 25. Cancer Treat Rev. 2011. PMID: 21612874 Review.
Cited by
-
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.Curr Pharm Des. 2013;19(4):578-613. doi: 10.2174/138161213804581918. Curr Pharm Des. 2013. PMID: 23016851 Free PMC article. Review.
-
MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.Oncogene. 2018 Jan 4;37(1):107-115. doi: 10.1038/onc.2017.293. Epub 2017 Sep 11. Oncogene. 2018. PMID: 28892045
-
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.Sci Transl Med. 2010 Oct 20;2(54):54ra77. doi: 10.1126/scitranslmed.3001338. Sci Transl Med. 2010. PMID: 20962331 Free PMC article.
-
Cancer and neurodegeneration: between the devil and the deep blue sea.PLoS Genet. 2010 Dec 23;6(12):e1001257. doi: 10.1371/journal.pgen.1001257. PLoS Genet. 2010. PMID: 21203498 Free PMC article. Review.
-
Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117. Epub 2013 Apr 18. Leukemia. 2013. PMID: 23702683 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
